United States Benzathine Penicillin G - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The united states benzathine penicillin g market size is projected to be USD 147.5 million in 2025, USD 157.12 million in 2026, and reach USD 215.47 million by 2031, growing at a CAGR of 6.52% from 2026 to 2031. This report is Segmented by Indication (Syphilis Treatment, Rheumatic Fever & RHD Prophylaxis, and More), Product Presentation (Prefilled Syringe, Powder and Diluent), End User (Hospitals, Clinics, Specialty Care Centers), and Procurement Channel (Wholesaler, Public Health Tenders, Emergency Import, Direct Institutional). Market Forecasts are Provided in Terms of Value (USD).

United States Benzathine Penicillin G Market Trends and Insights

Rising Congenital Syphilis Treatment Urgency

Congenital syphilis remains the clearest immediate demand trigger in the United States benzathine penicillin G market because the CDC reported nearly 4,000 newborn cases in 2024 and described that total as the twelfth straight annual increase and 700% above 2015 levels. The case total understates drug demand because every confirmed infant case can also lead to maternal treatment, partner treatment, and broader prenatal follow-up that consumes additional doses. This means that one reported event can translate into several treatment courses across connected care settings rather than a single isolated prescription. The heaviest pressure falls on Southern and Southwestern states, where case intensity is already high and public health programs often direct supply toward pregnant patients first. As a result, any disruption in manufacturing or allocation reaches the most urgent patients early and keeps the United States benzathine penicillin G market tightly linked to maternal and neonatal care capacity.

Persistent Adult Syphilis Caseload And Repeat-Dose Latent Therapy

The adult syphilis burden still supports broad baseline demand in the United States benzathine penicillin G market even though primary and secondary syphilis declined in 2024 from the prior year. Treatment intensity matters more than headline case counts because latent and late-latent disease require three weekly doses of 2.4 million units, which creates much higher volume per patient than early-stage infection. This dosing pattern turns latent cases into a strong volume driver that can remain hidden when planners focus only on reported incident infections. Demand also moves through the system more slowly than it does for acute symptomatic care, which can leave inventory planning out of step with actual refill needs. That lag helps sustain shortage conditions and keeps the United States benzathine penicillin G market exposed to repeat stress even when the most visible STI indicators appear to improve.

Single-Source Domestic Supply And Prolonged Shortage Risk

The largest restraint on the United States benzathine penicillin G market is the continued reliance on one FDA-approved domestic manufacturer. Pfizer's King Pharmaceuticals subsidiary remained the sole approved domestic source, which left the entire market exposed when shortage cycles persisted after April 2023 and when the July 2025 recall removed critical prefilled syringe lots from circulation. Pfizer's January 2026 update still showed allocation at the wholesaler level and delayed recovery for key presentations, and later updates extended recovery expectations further into 2027. The wider sterile injectable shortage pattern also matters because quality failures and limited margins have repeatedly disrupted low-cost injectable drugs across the healthcare system. That leaves the United States benzathine penicillin G market in a position where medical need exists, but treatable volume still depends on whether one supply chain can perform without interruption.

Other drivers and restraints analyzed in the detailed report include:

• Need For Long-Acting Rheumatic Fever Prophylaxis
• Temporary Import Pathways Expand Powder-Format Demand
• Sterile Injectable Manufacturing And Cold-Chain Complexity

Segment Analysis

Syphilis treatment accounted for 68.31% share in 2025, which kept it firmly at the center of the United States benzathine penicillin G market. That position reflects the continued scale of congenital and adult syphilis treatment need, with the CDC reporting nearly 4,000 congenital syphilis cases in 2024 and continued national STI pressure. Syphilis also has high clinical urgency because treatment cannot be delayed easily in pregnancy and latent infection often requires multi-dose therapy. Other indication categories remain smaller, but they are still medically necessary and do not behave like discretionary demand.

Rheumatic fever and rheumatic heart disease prophylaxis is projected to grow at 7.38% CAGR through 2026-2031, making it the fastest-expanding indication in the United States benzathine penicillin G market. WHO's 2024 guidance reinforced intramuscular prophylaxis as the preferred long-term approach and a strong recurrence advantage over oral therapy. This segment grows differently from syphilis because patients can remain on therapy for years and require repeated injections at regular intervals. That long-duration pattern means new patient starts continue to build demand even if syphilis case growth becomes less severe over time.

Prefilled syringes captured 73.24% share in 2025 and remained the dominant presentation within the United States benzathine penicillin G market. Their lead came from provider familiarity, faster administration, and lower preparation burden in busy clinical settings. That advantage was weakened by the 2025 recall, which removed important prefilled lots and exposed the risk of relying too heavily on one format and one domestic source. The recall period also pushed more providers to reassess their willingness to use formats that require reconstitution if that meant securing reliable supply.

Powder and diluent for suspension is projected to grow at 8.52% CAGR through 2026-2031, which makes it the fastest-growing product segment. FDA enforcement discretion brought Extencilline and Lentocilin into the country in this format, creating a practical supply path that had not existed before 2024. As high-volume public health sites gain more comfort with reconstitution, the workflow penalty becomes easier to manage. That supports lasting format diversification in the United States benzathine penicillin G market even after some domestic syringe supply returns.

Complete Report Scope:

• By Indication
  • Syphilis treatment
  • Rheumatic fever and rheumatic heart disease prophylaxis
  • Group A streptococcal infections
  • Other Indications
• By Product Presentation
  • Prefilled syringe
  • Powder and diluent for suspension
• By End User
  • Hospitals
  • Clinics
  • Specialty Care Centers
• By Procurement Channel
  • Wholesaler procurement
  • State and local public-health tenders
  • Emergency import channels
  • Direct institutional contracting

List of Companies Covered in this Report:

• AdvaCare
• Biopharma S.r.l.
• Centurion Healthcare
• CSPC Holdings Company Limited
• GNH India Pharmaceuticals Limited
• Laboratoires Delbert
• Laboratorios Atral
• Lavina Pharmaceuticals Pvt. Ltd.
• Lifechem Healthcare
• Orofino Pharmaceuticals Group
• Pfizer
• Provepharm
• Reyoung Pharmaceutical Co., Ltd.
• Shanghai Trifecta Pharma Co. Ltd.
• SiNi Pharma Pvt. Ltd.
• Wellona Pharma

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support